MIAMI, Jan. 18, 2021 /PRNewswire-PRWeb/ -- On a mission to educate consumers about the unique ingredient used in FEMAXEEN®'s product formulation, DNA® BIOPHARM (DNA®) leads their initiatives with discussions and materials that shed light on the ingredient UriCyTonin® and its inclusion in the female urinary incontinence supplement.
UriCyTonin® is a proprietary ingredient in FEMAXEEN®, formulated from purified pollen extracts including rye pollen helps to retain beneficial components for bladder health. Additionally, by including flower pollen extract as the second most notable ingredient in creating a healthy bladder environment for the detrusor smooth muscle, FEMAXEEN®'s clinical studies state that it sends signals to the detrusor smooth muscle, making it more alert for a healthier, more controllable bladder.
"UriCyTonin® has tremendous a beneficial effect on bladder control," states Oscar del Cid, President and CEO of DNA®. "Notably, the ingredient sends direct contractile responses of the M2 and M3 muscarinic receptors on the bladder smooth muscle, which in turn mediates actions to Acetylcholine, a neurotransmitter that sends signals to muscle cells."
According to published clinical studies, the inclusion of UriCyTonin® in FEMAXEEN® specifically helps the supplement work as an antagonist of the M3 muscarinic receptor, helping contractile function in the bladder. The result is a much stronger and effective supplement for bladder control and bladder health.
To purchase or learn more about FEMAXEEN® visit https://femaxeen.com.
About FEMAXEEN®
FEMAXEEN® is distributed by DNA BIOPHARM ® as s dietary supplement that supports lower urinary tract health. A complete solution for women's incontinence, FEMAXEEN® has been tested and evaluated through a randomized, double-blind, placebo-controlled study with findings citing a 45.3% reduction in incontinence within two months. Now available in the U.S., FEMAXEEN® can be purchased without a prescription.
About DNA BIOPHARM ®
Founded in 1992, DNA® has done business in over 25 countries, covering six continents, and currently operating in America (Miami), Mexico (Mexico City) Europe (Budapest, Hungary), and Africa (Cape Town, South Africa). In 2013, DNA Mexico became one of the largest distributors of The Day After Pill after introducing the pill in 2003 and selling about 30,000,000 units within a 10-year period. Today, DNA® continues to manufacture and distribute a comprehensive line of products that target a wide range of health issues ranging from immune deficiency, psoriasis, acne, adrenal stability, incontinence, and more. DNA® is poised to continue great leaps forward with their tradition of growth, quality, and service worldwide.
Media Contact
Ally Bertik, Marketing Maven, 3109947381, [email protected]
SOURCE DNA BIOPHARM
Share this article